Canton Strategic (CNTN) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Canton Strategic (CNTN) has outperformed Jyong Biotech (MENS) over the past year, losing 33.2% versus a loss of 96.1%. Canton Strategic is the larger company by market cap ($168.1 million vs $159.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | MENS |
|---|---|---|
| Share price | $2.11 | $2.10 |
| Market cap | $168.13M | $159.66M |
| 1-day change | +1.44% | 0.00% |
| YTD return | -30.36% | -46.84% |
| 1-year return | -33.23% | -96.12% |
| EPS (TTM) | $-0.10 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $63.00 |
| 52-week low | $1.75 | $1.43 |
| Distance from 52-week high | -69.38% | -96.67% |
| Average volume | 760.71K | 45.61K |
| Shares outstanding | 79.68M | 74.23M |
| Employees | 12 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed MENS by 62.9 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
CNTN vs MENS FAQ
Which is bigger, Canton Strategic or Jyong Biotech?
Canton Strategic (CNTN) is larger, with a market capitalization of $168.13M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, CNTN or MENS?
CNTN returned -33.23% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.